IGF Oncology to Present at Biotech Showcase 2019

ST. PAUL, Minn., /PRNewswire/ -- IGF Oncology, a clinical-stage company developing targeted therapies for cancer, today announced that its Founder and President, Hugh McTavish, Ph.D., will present at Biotech Showcase 2019, held January 6-9, 2019, at the Hilton San Francisco Union Square.

Dr. McTavish will present IGF Oncology's clinical pipeline, including its lead product, IGF-MTX, a conjugate of FDA-approved methotrexate with a proprietary derivative of insulin-like growth factor-1 (IGF) that is used to target the therapy to cancer cells that over-express the IGF receptor.

Details of IGF Oncology's presentation are as follows:

About IGF Oncology
IGF Oncology is a clinical-stage company developing targeted therapies for cancer. The Company's lead product, IGF-MTX, is a conjugate of the drug methotrexate and a proprietary recombinant protein derivative of insulin-like growth factor-1 (IGF), the receptor for which is over-expressed by a number of cancers. A clinical study showed that IGF-MTX was effective at a concentration 12-fold lower than the lowest prescribed dose of methotrexate, across multiple tumor types, and without the dose-limiting side effect of cytopenia. The Company is currently conducting a Phase 1b/2a study with the Mayo Clinic in patients with myelodysplastic syndrome (MDS) and raising additional capital to fund this asset through potential approval.

Contacts:

Tiberend Strategic Advisors, Inc. 
Brian Pinkston (Investors)
bpinkston@tiberend.com 
(212) 375-6298

David Schemelia (Media)
dschemelia@tiberend.com 
(212) 375-2686

View original content:http://www.prnewswire.com/news-releases/igf-oncology-to-present-at-biotech-showcase-2019-300769371.html

SOURCE IGF Oncology